Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections
Revive Therapeutics (OTCQB: RVVTF) has provided an update on their research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study, conducted in partnership with Defence R&D Canada – Suffield Research Centre, is now expected to be completed in October 2024. If results are promising, further studies may be initiated to facilitate FDA and Health Canada approvals for Bucillamine's use in nerve agent or organophosphate pesticide poisoning.
The company is also exploring Bucillamine's potential in viral infections, including monkeypox (Mpox). Bucillamine, a cysteine derivative with two thiol groups, has shown to be 16 times more potent as a thiol donor than N-acetyl-L-cysteine (NAC), which has demonstrated efficacy in attenuating symptoms of respiratory viral infections. Revive emphasizes that no claims are being made about Bucillamine's ability to treat or cure Mpox or other infectious diseases at this time.
Revive Therapeutics (OTCQB: RVVTF) ha fornito un aggiornamento sul loro studio di ricerca che valuta Bucillamine come potenziale trattamento per l'esposizione agli agenti nervini. Lo studio, condotto in collaborazione con il Defence R&D Canada – Suffield Research Centre, è ora previsto per essere completato entro ottobre 2024. Se i risultati saranno promettenti, potrebbero essere avviati ulteriori studi per facilitare le approvazioni della FDA e di Health Canada per l'uso di Bucillamine nell'intossicazione da agenti nervini o pesticidi organofosforici.
La società sta anche esplorando il potenziale di Bucillamine nelle infezioni virali, compreso il vaiolo delle scimmie (Mpox). Bucillamine, un derivato della cisteina con due gruppi tiolici, ha dimostrato di essere 16 volte più potente come donatore di tiolo rispetto all'N-acetil-L-cisteina (NAC), che ha dimostrato efficacia nell'attenuare i sintomi delle infezioni virali respiratorie. Revive sottolinea che al momento non vengono fatte affermazioni sulla capacità di Bucillamine di trattare o curare Mpox o altre malattie infettive.
Revive Therapeutics (OTCQB: RVVTF) ha proporcionado una actualización sobre su estudio de investigación que evalúa Bucillamina como un posible tratamiento para la exposición a agentes nerviosos. El estudio, realizado en colaboración con Defence R&D Canada – Suffield Research Centre, ahora se espera que se complete en octubre de 2024. Si los resultados son prometedores, se pueden iniciar más estudios para facilitar las aprobaciones de la FDA y Health Canada para el uso de Bucillamina en la intoxicación por agentes nerviosos o pesticidas organofosforados.
La compañía también está explorando el potencial de Bucillamina en infecciones virales, incluido el viruela de simios (Mpox). Bucillamina, un derivado de la cisteína con dos grupos tiol, ha demostrado ser 16 veces más potente como donador de tiol que el N-acetil-L-cisteína (NAC), que ha demostrado eficacia en la atenuación de los síntomas de infecciones virales respiratorias. Revive enfatiza que no se están haciendo afirmaciones sobre la capacidad de Bucillamina para tratar o curar Mpox o otras enfermedades infecciosas en este momento.
Revive Therapeutics (OTCQB: RVVTF)는 Bucillamine을 신경 작용제 노출에 대한 잠재적 치료제로 평가하는 연구에 대한 업데이트를 제공했습니다. Defence R&D Canada – Suffield Research Centre와의 협력으로 진행되는 이 연구는 이제 2024년 10월에 완료될 것으로 예상됩니다. 결과가 긍정적이라면, 신경 작용제나 유기 인산염 살충제 중독에 대한 Bucillamine 사용을 위한 FDA와 Health Canada의 승인을 촉진하기 위해 추가 연구가 시작될 수 있습니다.
회사는 또한 원숭이두창 (Mpox)을 포함한 바이러스 감염에 대한 Bucillamine의 잠재성을 탐색하고 있습니다. Bucillamine은 두 개의 티올 그룹을 가진 시스테인 유도체로, N-acetyl-L-cysteine (NAC)보다 티올 기부제로 16배 더 강력한 것으로 나타났으며, NAC는 호흡기 바이러스 감염 증상을 완화하는 데 효과를 보였습니다. Revive는 현재 Bucillamine이 Mpox 또는 다른 감염성 질병을 치료하거나 완치할 수 있다는 주장도 하지 않음을 강조합니다.
Revive Therapeutics (OTCQB: RVVTF) a fourni une mise à jour sur son étude de recherche évaluant Bucillamine comme traitement potentiel d'une exposition aux agents neurotoxiques. L'étude, réalisée en partenariat avec le Defence R&D Canada – Suffield Research Centre, devrait maintenant être achevée en octobre 2024. Si les résultats sont prometteurs, d'autres études pourraient être initiées pour faciliter les approbations de la FDA et de Santé Canada pour l'utilisation de Bucillamine dans le cas d'une intoxication par des agents neurotoxiques ou des pesticides organophosphorés.
L'entreprise explore également le potentiel de Bucillamine dans les infections virales, y compris la variole simienne (Mpox). Bucillamine, un dérivé de la cystéine avec deux groupes thiols, s'est avéré 16 fois plus puissant en tant que donneur de thiol que le N-acétyl-L-cystéine (NAC), qui a montré son efficacité à atténuer les symptômes des infections virales respiratoires. Revive souligne qu'aucune revendication concernant la capacité de Bucillamine à traiter ou guérir Mpox ou d'autres maladies infectieuses n'est faite actuellement.
Revive Therapeutics (OTCQB: RVVTF) hat ein Update zu ihrer Forschungsstudie bereitgestellt, in der Bucillamine als potenzielle Behandlung bei Neurotoxin-Exposition evaluiert wird. Die Studie, die in Zusammenarbeit mit Defence R&D Canada – Suffield Research Centre durchgeführt wird, wird voraussichtlich im Oktober 2024 abgeschlossen. Wenn die Ergebnisse vielversprechend sind, könnten weitere Studien begonnen werden, um die Genehmigungen von FDA und Health Canada für den Einsatz von Bucillamine bei der Vergiftung durch Neurotoxine oder Organophosphat-Pestizide zu erleichtern.
Das Unternehmen untersucht auch das Potenzial von Bucillamine bei Virusinfektionen, einschließlich Affenpocken (Mpox). Bucillamine, ein Cystein-Derivat mit zwei Thiolgruppen, hat sich als 16-mal potenter als Thiolspender im Vergleich zu N-acetyl-L-cystein (NAC) erwiesen, welches in der Linderung von Symptomen von respiratorischen Virusinfektionen wirksam ist. Revive betont, dass derzeit keine Aussagen zur Fähigkeit von Bucillamine gemacht werden, Mpox oder andere Infektionskrankheiten zu behandeln oder zu heilen.
- Research study on Bucillamine for nerve agent exposure progressing, expected completion in October 2024
- Potential expansion of Bucillamine's application to viral infections, including Mpox
- Bucillamine shown to be 16 times more potent as a thiol donor than NAC, which has demonstrated efficacy in viral infections
- No concrete results or efficacy data available yet from the research study
- No express or implied claims made about Bucillamine's ability to treat or cure Mpox or other infectious diseases
TORONTO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury. The research study is progressing and is expected to be now completed in October 2024.
The results from this research study, if promising, will determine further studies to facilitate FDA and Health Canada approvals for the use of Bucillamine in nerve agents or organophosphate pesticide poisoning, and explore its potential in viral infections, including monkeypox (“Mpox”). In 2023, the World Health Organization released a Mpox fact sheet suggesting that severe cases of Mpox result in a number of conditions including inflammation of the brain, heart, rectum, genital organs and urinary passages.1
A study in 2022 made the link between the administration of antioxidants and the improvement of virus-induced effects or to reduce viral replication yield. The suggestion that strong antioxidants such as N-acetyl-L-cysteine (“NAC”), butylated hydroxyanisole or Terameprocol could have an effect on Mpox viral infection in humans to ease severe symptoms.2 NAC has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to increase antioxidant activity of cellular glutathione.3-6
Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC.7 Thus, Bucillamine may be a candidate for the treatment or alleviation of symptoms related to Mpox infection.
The Company would like to make it clear that it is not making any express or implied claims that its product (Bucillamine) has the ability to treat, eliminate or cure Monkeypox (Mpox) and/or other infectious diseases at this time.
About Revive Therapeutics Ltd.
Revive Therapeutics is a life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. Revive prioritizes its drug development efforts to take advantage of several regulatory incentives awarded by the FDA, such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. Revive is also advancing the development of Psilocybin-based therapeutics through various programs. For more information, visit www.ReviveThera.com.
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “may”, “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Company’s cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company's management's discussion and analysis for the three and nine months ended March 31, 2024 ("MD&A"), dated May 28, 2024, which is available on the Company's profile at www.sedarplus.ca.
References:
- https://www.who.int/news-room/fact-sheets/detail/monkeypox
- Aydemir D, Ulusu NN. The possible importance of the antioxidants and oxidative stress metabolism in the emerging monkeypox disease: An opinion paper. Front Public Health. 2022 Oct 20;10:1001666.
- L. Carati et al, Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment., Eur Respir J. 1997 Jul;10(7):1535-41).
- M Mata et al, N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV)., Biochem Pharmacol. 2011 Sep;82(5):548-55.
- D Ungheri et al, Protective effect of n-acetylcysteine in a model of influenza infection in mice., Int J Immunopathol Pharmacol. 2000 Sep-Dec;13(3):123-128.
- RH Zhang et al, N-acetyl-l-cystine (NAC) protects against H9N2 swine influenza virus-induced acute lung injury., Int Immunopharmacol. 2014 Sep;22(1):1-8).
- LD Horwitz, Bucillamine: a potent thiol donor with multiple clinical applications, Cardiovasc Drug Rev. 2003 Summer;21(2):77-90).
FAQ
When is the Bucillamine research study for nerve agent exposure expected to be completed?
What potential applications is Revive Therapeutics (RVVTF) exploring for Bucillamine beyond nerve agent exposure?
How does Bucillamine compare to N-acetyl-L-cysteine (NAC) in terms of potency?
Is Revive Therapeutics (RVVTF) claiming that Bucillamine can treat or cure Mpox?
